Foundation Fighting Blindness Retinal Degeneration Fund 的 Form 4 申報
Opus Genetics, Inc.（IRD），2026/10/2 申報
- 申報編號
- 0002042266-26-000002
- 申報時間
- 2026/10/2 19:47 ET
- 交易日
- 2026/9/30
- 申報延遲
- 2 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 1 筆非衍生性交易。公開市場賣出合計 $275.6 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Foundation Fighting Blindness Retinal Degeneration FundCIK 0002042266 | 董事、其他：See Remarks |
| Foundation Fighting Blindness, Inc.CIK 0002042532 | 董事、其他：See Remarks |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/30 | Common Stock | S賣出處分 | −556,000 | $4.96F1 | −$2,755,980.8 | 3,236,171 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
This transaction was executed in multiple trades at prices ranging from $4.95 to $5.29. The price reported in Column 4 is a weighted average price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
備註
For purposes of Section 16 of the Exchange Act of 1934, as amended, the Reporting Persons may be deemed a director by deputization of Issuer by virtue of the fact that Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to serve on the board of directors of Issuer and Dr. Graves is the chair of the board of directors of RDF and a member of the board of directors of FFB and Dr. Bennett is a member of the board of directors of RDF.